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Background and Purpose—MRI biomarkers play an important role in the diagnostic work-up of dementia, but their
prognostic value is less well-understood. We investigated if simple MRI rating scales predict mortality in a memory
clinic population.
Methods—We included 1138 consecutive patients attending our memory clinic. Diagnostic categories were:
subjective complaints (n220), mild cognitive impairment (n160), Alzheimer disease (n357), vascular
dementia (n46), other dementia (n136), and other diagnosis (n219). Baseline MRIs were assessed using
visual rating scales for medial temporal lobe atrophy (range, 0 – 4), global cortical atrophy (range, 0 –3), and white
matter hyperintensities (range, 0 –3). Number of microbleeds and presence of infarcts were recorded. Cox-
regression models were used to calculate the risk of mortality.
Results—Mean follow-up duration was 2.6 (1.9) years. In unadjusted models, all MRI markers except infarcts predicted
mortality. After adjustment for age, sex, and diagnosis, white matter hyperintensities, and microbleeds predicted
mortality (white matter hyperintensities: hazard ratio [HR], 1.2; 95% CI, 1.0–1.4; microbleeds: HR, 1.02 95% CI,
1.00–1.03; categorized: HR, 1.5; 95% CI, 1.1–2.0). The predictive effect of global cortical atrophy was restricted to
younger subjects (HR, 1.7; 95% CI, 1.2–2.6). An interaction between microbleeds and global cortical atrophy indicated
that mortality was especially high in patients with both microbleeds and global cortical atrophy.
Conclusion—Simple MRI biomarkers, in addition to their diagnostic use, have a prognostic value with respect to mortality in
a memory clinic population. Microbleeds were the strongest predictor of mortality. (Stroke. 2009;40:492-498.)
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Predicting progression and outcome in dementia is clini-cally important. It provides important information for
patients and caregivers and improves patient management. It
also has scientific importance by giving insight in the
possible pathological processes involved in progression of
disease. The presence of dementia in general leads to an
increased mortality, and several clinical and demographic
characteristics have been identified that convey poor surviv-
al.1–3 Old age, male gender, and comorbidity are associated
with higher mortality, both in a general population2 and
among patients with dementia,1,2,4 although some studies
report that mortality attributable to dementia is higher in
young subjects compared to older subjects.5
MRI has an established role in the diagnostic work-up of
dementia, beyond the exclusion of potentially treatable
causes of dementia.6,7 MRI markers of atrophy can support
a diagnosis of Alzheimer disease (AD)8 and markers of
cerebrovascular disease are an essential part of the
NINDS-AIREN criteria for vascular dementia.9 Moreover,
global cortical atrophy (GCA) and medial temporal lobe
atrophy (MTA) predict decline of cognitive function.10,11 The
relation between MRI markers of vascular disease and cog-
nitive function is less clear; however, some studies suggest an
association12,13 but others fail to do so.10,14
Less is known about the value of MRI in predicting
survival in memory clinic patients. A limited number of
studies found a correlation between imaging markers and an
increased risk of mortality, and only 1 of those studies4 was
conducted in a dementia population, using CT rather than
MRI. The latter study described an association of temporopa-
rietal atrophy and mortality within a population of AD
patients. Other studies that described associations between
imaging markers and mortality were conducted either in an
elderly population without dementia,15,16 or in other disease
populations.17–19 The aim of the current study was to inves-
tigate the prognostic value with respect to mortality of 5
simple MRI markers related to neurodegenerative and vascu-
lar disease in a memory clinic population.
Received January 30, 2008; final revision received July 3, 2008; accepted July 22, 2008.
From Alzheimer Center, Department of Neurology (W.J.P.H., J.D.S., C.C., M.M.E.B., P.S., F.B., W.M.v.d.F.) and Department of Radiology (W.J.P.H.,
J.D.S., F.B.), VU University Medical Center, Amsterdam, The Netherlands; Department of Neurology and Stroke Department (C.C.), Lille University
Hospital, France.
Correspondence to W.J.P. Henneman, MD, Department of Radiology and Alzheimer Center, VU University Medical Center, PO Box 7057, 1007 MB
Amsterdam, The Netherlands. E-mail w.henneman@vumc.nl
© 2009 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.108.516286
492
Materials and Methods
Patients
The study population consisted of 1138 consecutive patients who
visited the memory clinic of the Alzheimer Center, VU University
Medical Center between 1993 and 2006, and underwent brain MRI.
Brain MRI scans were performed as part of the routine clinical
work-up. The other standardized clinical assessments included med-
ical history, physical examination, neurological examination, labo-
ratory tests, electroencephalography and neuropsychological exam-
inations. Diagnoses were made in a multidisciplinary consensus
meeting between neurologists, neuropsychologists, a clinical neuro-
physiologist, psychiatrist, geriatrician, and radiologist. We defined
the following categories of diagnosis: subjective complaints (cogni-
tive complaints in the absence of deficits on neuropsychological
examination), mild cognitive impairment,20,21 AD using the
NINCDS-ADRDA criteria,22 vascular dementia,9 other dementia
(including frontotemporal lobar degeneration,23 dementia with Lewy
bodies,24 and other neurodegenerative disorders), and other diagnosis
(including neurological, psychiatric, or other diagnoses and cases in
which diagnosis was postponed, eg, awaiting further examinations).
The study was approved by the local medical ethical committee,
and all patients gave written informed consent for their clinical data
to be used for research purposes at the time of their first visit.
Questionnaires were sent out to patients’ general practitioners and
follow-up was defined based on dates of survival or death on these
questionnaires. When the questionnaire was not returned, last date of
survival or date of death was retrieved from the patient’s clinical
record (n287). Information about medical history was retrieved
from the patients’ clinical records.
MRI Protocol
The majority of MRI scans (n998) were obtained on a 1.0-T
system (Siemens Magnetom Impact Expert); 140 scans were ob-
tained on a 1.5-T platform (Siemens Sonata Syngo or Siemens
Vision). Scan protocol included: (1) 3-dimensional T1-weighted
magnetization-prepared rapid acquisition gradient-echo sequence
(coronal orientation, 148–176 slices; 1.5-mm slice thickness; field of
view, 250 mm; 256256 matrix; echo time (TE), 5.2–7.0 ms;
repetition time (TR), 15 ms; inversion time (TI), 300 ms); (2)
fluid-attenuated inversion recovery sequence (transverse orientation,
17 slices; slice thickness, 5 mm; slice gap, 1.5–2.0 mm; field of view,
250 mm; 256256 matrix; TE, 101–105 ms; TR, 9000 ms; TI, 2200
ms); (3) T2-weighted turbo spin echo sequence (transverse orienta-
tion, 21 slices; slice thickness, 5 mm; slice gap, 1.5 mm; field of
view, 250 mm; 256256 matrix; TE, 119 ms; TR, 5775 ms); and (4)
T2*-weighted gradient-echo sequence (transverse orientation, 19–21
slices; slice thickness, 5 mm; slice gap, 1.0 mm; field of view,
250 mm; 256256 matrix; TE, 15–22 ms; TR, 600–800 ms; flip
angle, 15°–20°).
MRI Assessment
Assessment of MRI consisted of 3 widely used visual rating scales
(using previously described operationalization criteria25–27), a count
of microbleeds, and assessment of the presence of large vessel
infarcts. MTA was rated using a 5-point rating scale (0–4)27 using
oblique reconstructions of the magnetization-prepared rapid acqui-
sition gradient-echo sequences, perpendicular to the long axis of the
hippocampus. In the analysis, we used the average of MTA score for
the left and right sides. GCA (range, 0–3)26 and white matter
hyperintensities (WMH) (range, 0–3)25 were assessed on fluid-
attenuated inversion recovery images. We defined microbleeds as
round lesions with low signal on T2*-weighted images within the
brain parenchyma (diameter 10 mm).28 The total number of
microbleeds was counted. Presence of 1 infarcts, including both
territorial and watershed infarctions, was recorded.
The rating was performed by 3 observers, blinded to the patients’
clinical data. The observers were trained using our standard training
set (19 brains) to meet consistency requirements according to our
standard operating procedure. The interrater-weighted Cohen 
scores were 0.90 for microbleeds, 0.80 for MTA and WMH
scores, and 0.60 for GCA (against internally established gold
standard). Intrarater-weighted Cohen  scores were 0.90 for
microbleeds, 0.80 for MTA, and 0.70 for GCA and WMH.
Because of missing sequences, or impaired quality of sequences,
MTA could only be assessed in 1112 cases, GCA could only be
assessed in 1090, and WMH could only be assessed in 1117. Because
the T2*-weighted sequence has been included in the standard scan
protocol more recently, microbleeds could be assessed in a smaller
number of scans than the other measures (n938).
Statistical Methods
For statistical analyses, SPSS version 12.0.1 for windows was used.
Differences between groups were analyzed using 2 test and Student
t test. Kaplan-Meier survival curves were constructed for the scores
of the visual rating scales. To estimate the risk of mortality
associated with the MRI markers, Cox proportional hazards models
were used. We performed the analyses for microbleeds in 2 ways,
using the total number of microbleeds, and using a categorization (0,
1–2, 3), because the latter allows for easier comparison with the
hazard ratios (HR) of the other MRI markers. Per MRI marker, we
applied 5 models. Each MRI marker was entered univariately (model
1); adjusted for age and sex (model 2); adjusted for age, sex, and
diagnosis (model 3); and additionally adjusted for history of hyper-
tension, diabetes mellitus, hypercholesterolemia, and myocardial
infarction (model 4). Finally, all MRI measures were entered
simultaneously in model 5, with all covariates from model 4. To
investigate the predictive effects of WMH and microbleeds in further
detail, we repeated the analysis, entering them as categorical vari-
ables to model 3. To assess interactions between age and MRI
markers, and mutual interactions between the MRI markers, we
subsequently introduced bivariate interaction terms. For the assess-
ment of interactions with age, we entered age as a dichotomous
variable, based on median age (68 years). The models used to assess
interactions between MRI markers contained 2 MRI markers and
their interaction term with age, sex, and diagnosis as covariates.
Finally, we repeated the analyses for the group of AD patients only,
using the same 4 Cox proportional hazard models.
Results
Baseline characteristics for all patients are shown in Table 1.
The total number of patients who had died at follow-up was
153 (13%), after a mean follow-up duration of 2.6 (1.9)
years. The mean duration of follow-up did not differ between
patients who had deceased and those who were alive at
follow-up (P1.0). There were 628 (55%) men and 510 (45%)
women. Mortality was higher in men compared with women
(P0.001). Mean age at the time of MRI was 66 years (11),
and age at MRI was higher among patients who had deceased
compared with those who were still alive at follow-up
(P0.001). The numbers of patients per category of diagnosis
were: subjective symptoms, 220 (19%); mild cognitive impair-
ment, 160(14%); AD, 357 (31%); vascular dementia, 46 (4%);
other dementia, 136 (12%); and other diagnosis, 219 (19%).
Mortality was higher among patients with dementia com-
pared with the patients in the subjective symptoms and mild
cognitive impairment groups (P0.001 for AD and vascular
dementia; P0.005 for other dementia). Mean mini-mental
state examination score was lower in the patients who had
deceased at follow-up compared with those who were still
alive. Mean mini-mental state examination, by diagnosis,
ranged from 29 (subjective symptoms) to 21 (AD).
The Figure shows Kaplan-Meier survival curves for the
MRI markers in the overall population. Cox proportional
hazard models (Table 2) show that all MRI markers except
infarcts predicted mortality in the univariate analysis and
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after adjustment for age and sex (models 1 and 2). Microb-
leeds had the strongest impact on mortality, which became
especially clear after additional adjustment for diagnosis
(model 3), while WMH also had a modest predictive effect.
The effects were largely unchanged after entering history of
hypertension, diabetes, hypercholesterolesterolemia, and
myocardial infarction to the analysis. In the model in which
all MRI measures were entered simultaneously, microbleeds
remained a predictor of mortality, independent of the other
MRI measures. To assess the predictive effects of microb-
leeds and WMH in more detail, we entered them as categor-
ical variables to model 3. For both markers, the predictive
effects mainly depended on the group with severe abnormal-
ity (severe WMH [no WMHreference]: HR, 1.7; 95%
CI, 1.0 –2.8; P0.06; many [3] microbleeds [no
microbleedsreference]: HR, 2.4; 95% CI, 1.4–4.3;
P0.05). The HR for 1 and 2 WMH (no WMHreference)
were 1.0 (95% CI, 0.6–1.5; P0.94) and 1.0 (95% CI, 0.6-.8;
P0.90), respectively. For 1 to 2 microbleeds, HR was 0.8
(95% CI, 0.4–1.6; P0.60).
There was an interaction between age and GCA (P0.01),
but there was no significant interaction between age and the
other MRI markers. To explore how the predictive effect of
GCA was modified by age, we stratified the patients by
median age (68 years). Adjusted for sex and diagnosis, GCA
was a predictor of mortality in the younger patients (HR, 1.7;
95% CI, 1.1–2.6; P0.05), but not in older patients (HR, 1.0;
95% CI, 0.8–1.3; P0.80).
When entering bivariate interaction terms between pairs of
MRI markers to model 3, we found 2 interactions. First, there
was an interaction between MTA and GCA (P0.05). The
risk of mortality related to MTA was highest in patients with
a low GCA score, and the risk of mortality related to GCA
was highest in patients with low MTA scores. Second, we
found an interaction between GCA and number of microb-
leeds (P0.05). The risk of mortality for patients with
microbleeds was highest in those who additionally had high
GCA scores. The risk of mortality for patients with both
severe cortical atrophy (GCA score3) and 3 microbleeds
was 6-times the risk found in patients without cortical atrophy
and microbleeds (HR, 5.8; 95% CI, 1.5–22.9; P0.05).
Finally, we repeated the analyses for the group of AD
patients only (n357). Mean age was 70 years (9) and there
were relatively more female (196; 55%) than male patients
(161; 45%). Results were largely comparable with the results
in the total population (Table 3). After adjustment for age and
sex, the predictive effect of MTA and GCA disappeared,
whereas the number of microbleeds predicted mortality in the
group of AD patients independent of age and sex. The overall
predictive effect of WMH did not reach significance in any of
the models. The presence of infarcts did not predict mortality.
The effects were not altered after adjusting for the additional
covariates in model 3, and the predictive effect of microb-
leeds was independent of the other MRI variables.
Discussion
The main finding of this study is that baseline MRI biomar-
kers, especially microbleeds and to a lesser extent WMH,
predicted mortality in a memory clinic population. Large-
vessel infarcts did not predict mortality. The predictive effect
of cortical atrophy was restricted to the younger patients.
When we restricted the analysis to AD patients only, findings
were largely comparable.
Of the 5 MRI markers we investigated, presence of
microbleeds was the strongest predictor of mortality. Where
MTA and GCA are important markers in the diagnostic
process, because they can both help differentiate neurodegen-
erative disease from controls8 and are related to cognitive
function,10,11 we found that their value in predicting mortality
is strongly related to diagnosis. Whereas the relation between
markers of small-vessel disease and cognitive function re-
mains less clear,10,12–14 and microbleeds at present do not
have an important role the diagnostical process of dementia,
we show that the number of microbleeds and, to a lesser
extent, WMH are clinically relevant markers because they
predict mortality in this population. Our finding that infarcts
do not predict mortality within a memory clinic population is
in line with findings by others.4
To our knowledge, this is the first study assessing the
predictive value of microbleeds with respect to mortality in a
population other than a stroke population. Recent studies
have shown that the prevalence of microbleeds on MRI is
relatively high within a dementia population, and that the
presence of microbleeds is related to age, diagnosis, and the
Table 1. Baseline Characteristics
Alive Deceased Total
Total 985 (87%) 153 (13%) 1138
Sex
Female 463 (91%) 47 (9%) 510
Male 522 (83%) 106 (17%)* 628
Age 66 (11) 71 (9)† 66 (11)
Duration of follow-up 2.6 (1.9) 2.6 (1.9) 2.6 (1.9)
Diagnosis
Subjective complaints 213 (97%) 7 (3%) 220
MCI 150 (94%) 10 (6%) 160
AD 284 (80%) 73 (20%)‡ 357
Vascular dementia 31 (67%) 15 (33%)‡ 46
Other dementia 109 (80%) 27 (20%)‡ 136
Other diagnosis 198 (90%) 21 (10%) 219
MMSE 25 (5) 22 (6)† 25 (5)
Hypertension§ 248 (89%) 32 (11%) 280
Diabetes§ 69 (80%) 17 (20%) 86
Hyperchol§ 80 (88%) 11 (12%) 91
MI§ 42 (82%) 9 (18%) 51
Data represent absolute number (percentage) of patients except for age,
follow-up and MMSE, where numbers represent mean (SD). Percentages are
relative to the numbers shown in the column ‘Total’.
MCI indicates mild cognitive impairment; AD, Alzheimer disease; MMSE,
Mini-Mental State Examination; hyperchol, hypercholesterolemia; MI, myocar-
dial infarction.
*P0.001 (2; compared with female patients).
†P0.001 (t test).
‡P0.005 (2; compared with both subjective complaints and MCI).
§Available for n1096 (hypertension), n1111 (diabetes), n1121 (hyper-
cholesterolemia) and n1123 (myocardial infarction).
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presence of other findings of vascular pathology on
MRI.28 –30 Although 2 studies have described a relation
between the presence of microbleeds on MRI and severity
of cognitive impairment within a vascular dementia 31 and
a stroke32 population, the clinical significance of microb-
leeds is not fully clear at present. We add an important piece
of information by showing that microbleeds are associated with
poorer survival. Although microbleeds are highly prevalent
among patients with intracerebral hemorrhages and ischemic
stroke, literature about the risk of future cerebrovascular
events is scarce.33,34 It is tempting to assume that the observed
association between microbleeds and mortality is accounted
for by cerebrovascular causes of death. However, because we
were not able to collect data about cause of death of all
deceased patients and because the reason of death was too
often unknown, we were not able to perform analysis on these
data. Further studies should address the important issue of the
relation of microbleeds (and other MRI findings) and cause of
death.
Our data suggest that not merely the presence, but rather
the number, of microbleeds predicts the risk of mortality.
The categorized (0, 1–2, 3 microbleeds) analysis shows
that only the presence of many (3) microbleeds predicts
mortality. It should, however, not be concluded that there
Figure. Kaplan-Meier survival curves of
MRI markers. Kaplan Meier curves for
(A) MTA; (B) GCA; (C) WMH; (D)
microbleeds; and (E) infarcts. Lines
represent cumulative survival for each
different MTA, GCA and WMH score
and for number of microbleeds. Tables
under the curves represent the number
of patients entering the intervals of 0,
2, and 4 years of follow-up.
Henneman et al MRI Markers of Mortality in Memory Clinic Patients 495
is a strict threshold going from 2 to 3 microbleeds. Rather,
our results indicate that the presence of multiple microb-
leeds does predict mortality, whereas the presence of some
microbleeds is not associated with an increased risk of
mortality.
The interaction between microbleeds and cortical atrophy
resulted in a 6-fold increased risk of death for patients with
severe cortical atrophy and multiple microbleeds in compar-
ison with subjects without cortical atrophy and microbleeds.
Literature shows that atrophy is present in vascular dis-
ease,35,36 and vascular damage often occurs in AD.37 More-
over, neuropathological studies have suggested that neurode-
generative disease and vascular pathology act in synergy,
resulting in a higher risk of dementia and more severe
cognitive impairment.38,39 In vivo studies using MRI have
shown similar results.40,41 We extend on these findings by
showing that patients expressing both types of pathology on
MRI are at a far higher risk of mortality than patients with
either of them. Although one might hypothesize that microb-
leeds and cortical atrophy could coexist as a representation of
amyloid-angiopathy, recent findings that microbleeds seem to
have no or only little influence on cerebral atrophy in
CADASIL36 suggest that different pathological pathways
might be involved as well. Age modified the relation between
cortical atrophy and mortality. In the younger patients GCA
predicts mortality, but it does not do so in the older patients.
This might explain why the overall effect of GCA did not
reach statistical significance in the overall population.
Among the limitations of this study is the fact that, rather
than an epidemiological population-based study in which a
given number of subjects is followed for a fixed number of
years, our study is a cohort study in a clinical setting. The
consequentially high variability in duration of follow-up was,
nevertheless, accounted for in the statistical analyses. Second,
although the cohort consists of a clinically important selec-
tion of patients, the results might not be applicable to a
general population. In the Cox-proportional hazards models,
age, sex, diagnosis, and vascular risk factors were included as
covariates. We were not able to include other predictors of
mortality that have been described, such as (nonvascular)
Table 2. Risk Estimates of Mortality: Overall Population (n1138)
Model 1 Model 2 Model 3 Model 4 Model 5
MTA 1.5 (1.3–1.7)* 1.3 (1.1–1.5)* 1.1 (0.9–1.3) 1.1 (0.9–1.3) 1.1 (0.8–1.4)
GCA 1.6 (1.3–2.0)* 1.3 (1.0–1.6)† 1.2 (0.9–1.4) 1.2 (1.0–1.5) 1.2 (0.9–1.6)
WMH 1.5 (1.2–1.7)* 1.3 (1.1–1.5)* 1.2 (1.0–1.4)‡ 1.2 (1.0–1.4)‡ 1.1 (0.9–1.4)
MB N 1.02 (1.01–1.03)* 1.02 (1.01–1.03)* 1.01 (1.00–1.03)† 1.01 (1.00–1.03)† . . .
MB categories 2.0 (1.5–2.6)* 1.5 (1.2–2.0)* 1.4 (1.1–1.9)† 1.6 (1.2–2.1)* 1.6 (1.1–2.2)*
Infarcts 1.7 (0.9–3.4) 1.4 (0.7–2.7) 1.2 (0.6–2.4) 1.2 (0.6–2.4) 0.6 (0.3–1.4)
Data represent HR (95% CI) for mortality.
Model 1: uncorrected; model 2: adjusted for age and sex; model 3: adjusted for age, sex, and diagnosis; model 4: adjusted for age, sex, diagnosis,
and history of hypertension, diabetes mellitus, hypercholesterolemia, and myocardial infarction; model 5: all MRI measures entered in 1 model, with
covariates of model 4. In model 5, microbleeds were entered as a categorical variable, and results were comparable with the total number of
microbleeds (data not shown).
MB N indicates number of microbleeds (total N; range, 0–200); MB categories, microbleeds (0, 1–2, 3).
MTA, mean of score for left and right side, range, 0–4; GCA, range, 0–3; WMH, range, 0–3; infarcts, presence of 1 large-vessel infarcts.
*P0.01.
†P0.05.
‡P0.1.
Table 3. Risk Estimates of Mortality: Patients With AD (n357)
Model 1 Model 2 Model 3 Model 4
MTA 1.2 (1.0–1.5)‡ 1.0 (0.8–1.3) 1.0 (0.8–1.3) 1.0 (0.7–1.4)
GCA 1.4 (1.0–1.9)‡ 1.2 (0.9–1.7) 1.3 (0.9–1.9) 1.5 (0.9–2.4)
WMH 1.2 (0.9–1.6) 1.1 (0.9–1.5) 1.1 (0.9–1.5) 1.1 (0.8–1.7)
MB N 1.07 (1.04–1.11)* 1.07 (1.03–1.11)* 1.07 (1.03–1.11)* . . .
MB categories 1.7 (1.1–2.5)† 1.6 (1.0–2.4)† 1.8 (1.1–2.8)† 1.8 (1.1–3.0)†
Infarcts 2.3 (0.8–6.3) 2.0 (0.7–5.6) 1.8 (0.6–5.2) 0.9 (0.2–3.2)
Data represent HR (95% CI) for mortality.
Model 1: uncorrected; model 2: adjusted for age and sex; model 3: adjusted for age, sex, and history of hypertension,
diabetes mellitus, hypercholesterolemia, and myocardial infarction; model 4: all MRI measures entered in 1 model, with
covariates of model 3. In model 4, microbleeds were entered as a categorical variable, and results were comparable with
the total number of microbleeds (data not shown).
GCA, range, 0–3; infarcts, presence of1 large-vessel infarcts; MB categories, microbleeds (0, 1–2,3); MB N, total
number, range, 0–55; MTA, mean of score for left and right side, range, 0–4; WMH, range, 0–3.
*P0.01.
†P0.05.
‡P0.1.
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comorbidity and physical performance, because these data,
derived from clinical files, were not uniformly assessed and
were less complete than data on vascular risk factors. No
conclusions about the comparison between the predictive
values of MRI variables and other predictors of mortality,
such as age, diagnosis, and comorbidity, can be drawn from
our results. Taken into account that MRI is at present widely
available, as it is used in the diagnostic work-up of memory
clinic patients, our finding that simple MRI markers, in
addition to their diagnostic value, have prognostic value in
predicting mortality is clinically important. The information
obtained from MRI should be weighted together with other
clinical variables such as comorbidity in planning of patient
care and information given to patients and caregivers about
prognosis.
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